JP Morgan Chase’s Stealth BioTherapeutics Corp. ADS MITO Stock Holding History

JP Morgan Chase’s Portfolio MITO Stock Details MITO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-201	Closed	–	–	7247
2021 Q4	$0	Buy	+201	New	+$210	﹤0.01%	7181

Other funds holding MITO

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase's MITO Position: Q1 2022 in Review

JP Morgan Chase sold out of Stealth BioTherapeutics Corp. ADS (MITO) in Q1 2022, closing a stake of 201 shares.

JP Morgan Chase first reported a position in MITO in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 13 funds tracked by Wall St. Rank hold MITO as of Q1 2022.

JP Morgan Chase reported no remaining Stealth BioTherapeutics Corp. ADS position as of Q1 2022 after selling out during the quarter.
JP Morgan Chase sold 201 Stealth BioTherapeutics Corp. ADS shares in Q1 2022.
JP Morgan Chase first reported a position in Stealth BioTherapeutics Corp. ADS in Q4 2021 and held it in 1 quarter.
JP Morgan Chase's Stealth BioTherapeutics Corp. ADS position peaked at $0 in Q4 2021.
13 funds tracked by Wall St. Rank held Stealth BioTherapeutics Corp. ADS as of Q1 2022.

Based on JP Morgan Chase's 13F filing for Q1 2022, filed 11 May 2022.